AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Mar, 21, 2023
Anavex's A2-73 Blarcamesine's trial result... See more
Mar, 20, 2023
Complete Results!! !
PALI
Palisade Bio Inc
-19.56%
$2.25 - $1.81
Feb 7th 2023 - Mar 21st 2023
AUPH
Aurinia Pharmaceuticals Inc
3.07%
$8.48 - $8.74
Feb 8th 2023 - Mar 22nd 2023
Mar, 20, 2023
Up 56% from last year this time, and up 67% from l... See more
Mar, 14, 2023
Only info from PG: this Quarter is good.
Mar, 21, 2023
Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.
Mar, 20, 2023
Complete Results!! !
Mar, 16, 2023
But the company actually has never seen before wonderful results.
Feb, 26, 2023
If results hold up, the stock will achieve massive gains.
Feb, 26, 2023
The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.
Feb, 14, 2023
Alzheimer's is the most valuable and most difficult indication and most desired lately.. and only Anavex really has some great results with a great safety record. .
Jan, 24, 2023
The sava results trounce you guys 🤦🏻♂️🤦🏻♂️🤦🏻♂️😂😂😂
Jan, 24, 2023
Sava has potential and the phase 3 results will show the truth.
Jan, 24, 2023
Sava has good results. .
Jan, 2, 2023
They voluntarily suspended phase 3 bc they are seeing such a good results.
Mar, 20, 2023
Up 56% from last year this time, and up 67% from last quarter this time.
Mar, 14, 2023
Only info from PG: this Quarter is good.
Mar, 14, 2023
$AUPH Quarter looks good.
Mar, 10, 2023
Up 65% from last year this time, and up 61% from last quarter this time.
Mar, 8, 2023
AUPH has strong market potential, positive clinical results, growing revenue, and solid financial position, and is well-positioned for future growth and success.
Mar, 3, 2023
Up 70% from last year this time, and up 53% from last quarter this time.
Feb, 17, 2023
Regardless, so far it’s been a great quarter.
Oct, 21, 2022
As you can see I’m far more capable than my predecessors and far more accredited to produce results.
Oct, 21, 2022
Well good news at ERQ3 when Petie will show that his exhaustive research showed that there is seasonality to sales and explains Q3 flat results.
Oct, 20, 2022
$AUPH highest daily volume since ER last quarter - great daily candle.